New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
Subscribe To Our Newsletter & Stay Updated
